

Biography and CV

Name: Giovanni Grignani, MD

Born in Padua (Italy), 13th/May/1963

Study Location Address : Strada Provinciale 142, 10060 Candiolo, Torino Italy
 Telephone: +39 011.9933623
 Fax: +39 011.9933290
 e-mail: giovanni.grignani@ircc.it

Degrees and Qualifications:

Fellowship in Oncology (70/70 cum laude)	OCT, 2001
Fellowship in Internal Medicine (50/50)	15-JUL, 1993
Board Certificate in Medicine	29-DEC, 1988
Degree in Medicine, University of Pavia-Italy (110/110 cum laude)	21-JUL, 1988
School Leaving Certificate, Classic Lyceum (53/60)	JUL, 1982

Current Position

Attending physician, Dpt. of Medical Oncology at the Fondazione del Piemonte per l'Oncologia - Institute for Cancer Research and Treatment in Candiolo (Turin) Italy. Experienced in the conduction of clinical trials according to the GCP procedures.

Previous Professional Experience

Deputy Director Medical Oncology at the Institute for Cancer Research and Treatment (IRCC), Candiolo (Turin), Italy.	1998-now
Deputy Director, Oncological Day Hospital Mauriziano Hospital, Lanzo (Turin), Italy.	1997-1998
Assistant, Division of Internal Medicine, Mauriziano Hospital, Lanzo (Turin), Italy.	1993-1999
Assistant, Division of Internal Medicine. S. Andrea Hospital, Vercelli, Italy.	1992-1993
Residency, Division of Oncology and Internal Medicine, University of Pavia.	1988-1992

Post-Graduate Training

Training course in Palliative Care (Piedmont Region from June to October 1998).

Clinical Research Experience

Participation to phase I, II and III protocols of chemotherapy and immunotherapy in multiple myeloma, malignant lymphomas, soft tissue and bone sarcomas in Good Clinical Practice (GCP).

Development of prognostic tools in Onco-Hematology.

Development of target therapies in bone and soft tissue sarcomas

Translational research in bone and soft tissue sarcomas

International collaborations

Institutional representative of EURACAN

Institutional representative of EORTC

Institutional representative of FOSTER

Leading roles

National secretary of the Italian Sarcoma Group

National Secretary AIOM guidelines "Sarcoma"

Coordinator of the study Group "Rare Tumors" for the Piedmont regional network.

Memberships

Full member of: Italian Association of Medical Oncology (AIOM); American Society for Clinical Oncology (ASCO); European Society for Clinical Oncology (ESMO); Connective Tissue Oncology Society (CTOS); Italian Sarcoma Group (ISG)

Publications in the last three years and selected relevant publications

Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, **Grignani G**, Brunello A, Blay JY, Tendero O, Diaz-Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Miceli R, Casali PG, Gronchi A. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. *Cancer*. 2022 Jan 1;128(1):85-93. doi: 10.1002/cncr.33895. Epub 2021 Oct 13. PMID: 34643947.

Pignochino Y, Crisafulli G, Giordano G, Merlini A, Berrino E, Centomo ML, Chiabotto G, Brusco S, Basiricò M, Maldì E, Pisacane A, Leuci V, Sangiolo D, D'Ambrosio L, Aglietta M, Kasper B, Bardelli A, **Grignani G**. PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study. *Cancers (Basel)*. 2021 Dec 15;13(24):6295. doi: 10.3390/cancers13246295. PMID: 34944915; PMCID: PMC8699802.

Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne SL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo DF, Palmerini E, Stacchiotti S, Quagliuolo VL, Lopez-Pousa A, **Grignani G**, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG, Gronchi A. Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial. *Mol Cancer Ther*. 2021 Dec;20(12):2539-2552. doi: 10.1158/1535-7163.MCT-21-0315. Epub 2021 Sep 22. PMID: 34552008.

Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Blay JY, Strauss D, Rutkowski P, Ahuja N, Gonzalez R, **Grignani G**, Quagliuolo V, Stoeckle E, Lahat G, De Paoli A, Pillarisetty VG, Canter RJ, Mullen JT, Pennacchioli E, van Houdt W, Swallow CJ, Schrage Y, Cardona K, Fiore M, Gronchi A, Bagaria SP. Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Surg Oncol*. 2021 Nov;28(12):7854-7863. doi: 10.1245/s10434-021-10024-y. Epub 2021 Apr 27. PMID: 33907921.

Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S, Centomo ML, Leuci V, D'Ambrosio L, Aglietta M, Sangiolo D, **Grignani G**, Pignochino Y. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma. *Cells*. 2021 Oct 26;10(11):2893. doi: 10.3390/cells10112893. PMID: 34831119; PMCID: PMC8616526.

Bagaria SP, Swallow C, Suraweera H, Raut CP, Fairweather M, Cananzi F, Quagliuolo V, **Grignani G**, Hompes D, Ford SJ, Nessim C, Apte S, Skoczylas J, Rutkowski P, Bonvalot S, Tzanis D, Gabriel E, Pennacchioli E, Albertsmeier M, Canter RJ, Pollock R, Grignol V, Cardona K, Gamboa AC, Novak M, Stoeckle E, Almquist M, Ahuja N, Klemen N, Van Houdt W, Gyorki D, Gangi A, Rastrelli M, van der Hage J, Schrage Y, Valeri S, Conti L, Spiegel MR, Li Z, Fiore M, Gronchi A. Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. *Ann Surg Oncol*. 2021 Oct;28(11):6882-6889. doi: 10.1245/s10434-021-09739-9. Epub 2021 Mar 19. PMID: 33740198.

Ascierto PA, Orlova K, **Grignani G**, Dudzisz-Śledź M, Fenig E, Chiarion Sileni V, Fazio N, Samimi M, Mortier L, Gebhardt C, Kramkimel N, Steven N, Bechter O, Arance A, Benincasa E, Kostkova L, Costa N, Lorigan P. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. *Int J Cancer*. 2021 Dec 1;149(11):1926-1934. doi: 10.1002/ijc.33746. Epub 2021 Aug 3. PMID: 34310716.

Asaftei SD, Puma N, Paioli A, Petraz M, Morosi C, Podda M, Tamburini A, Palmerini E, Coccoli L, **Grignani G**, Manzitti C, Bertulli R, De Leonardis F, Rabusin M, Campello A, Tirtei E, Picci P, Prete A, Longhi A, Fagioli F, Luksch R. Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. *Cancers (Basel)*. 2021 Jun 18;13(12):3046. doi: 10.3390/cancers13123046. PMID: 34207428; PMCID: PMC8234176.

Abate ME, Cammelli S, Ronchi L, Diletto B, Gandola L, Paioli A, Longhi A, Palmerini E, Puma N, Tamburini A, Mascarini M, Coassin E, Prete A, Asaftei SD, Manzitti C, Bisogno G, Pierobon M, Coccoli L, Capasso M, **Grignani G**, Milano GM, Kiren V, Fagioli F, Ferrari S, Picci P, Carretta E, Luksch R. Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. *Cancers (Basel)*. 2021 Jun 3;13(11):2789. doi: 10.3390/cancers13112789. PMID: 34205124; PMCID: PMC8199967.

Iuliano L, Drioli S, Pignochino Y, Cafiero CM, Minisini M, D'Este F, Picco R, Dalla E, Giordano G, **Grignani G**, Di Giorgio E, Benedetti F, Felluga F, Brancolini C. Enhancing Proteotoxic Stress in Leiomyosarcoma Cells Triggers Mitochondrial Dysfunctions, Cell Death, and Antitumor Activity in vivo. *Mol Cancer Ther*. 2021 Jun;20(6):1039-1051. doi: 10.1158/1535-7163.MCT-20-0521. Epub 2021 Mar 30. PMID: 33785653.

Fife K, Tétu P, Prabhakaran J, Lebbé C, **Grignani G**. Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in

Europe. *Front Oncol.* 2021 May 28;11:672021. doi: 10.3389/fonc.2021.672021. PMID: 34123840; PMCID: PMC8194357.

Nannini M, Rizzo A, Nigro MC, Vincenzi B, Mazzocca A, **Grignani G**, Merlini A, D'Ambrosio L, Tolomeo F, Badalamenti G, Incorvaia L, Bonasera A, Fumagalli E, Miliziano D, Ligorio F, Brunello A, Chiusole B, Gasperoni S, Novelli M, Pantaleo MA. Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. *ESMO Open.* 2021 Aug;6(4):100222. doi: 10.1016/j.esmoop.2021.100222. Epub 2021 Aug 2. PMID: 34352702; PMCID: PMC8350191.

Cannella R, Tabone E, Porrello G, Cappello G, Gozzo C, Incorvaia L, **Grignani G**, Merlini A, D'Ambrosio L, Badalamenti G, Regge D, Bartolotta TV. Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. *Eur Radiol.* 2021 Nov;31(11):8554-8564. doi: 10.1007/s00330-021-07961-3. Epub 2021 Apr 21. PMID: 33881567.

Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, **Grignani G**, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. *Future Oncol.* 2021 Aug;17(22):2923-2939. doi: 10.2217/fon-2021-0284. Epub 2021 Apr 15. PMID: 33855868.

Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke A, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Broto JM, **Grignani G**, Jones RL, Kawai A, Tysarowski A, Mariani L, Casali PG, Stacchiotti S. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. *Cancer Med.* 2021 Apr;10(8):2645-2659. doi: 10.1002/cam4.3807. Epub 2021 Mar 13. PMID: 33713582; PMCID: PMC8026938.

Carnevale-Schianca F, Caravelli D, Gallo S, Becco P, Paruzzo L, Poletto S, Polo A, Mangioni M, Salierno M, Berger M, Pessolano R, Saglio F, Gottardi D, Rota-Scalabrini D, **Grignani G**, Fizzotti M, Ferrero I, Frascione PMM, D'Ambrosio L, Gaidano V, Gammaitoni L, Sangiolo D, Saglietto A, Vassallo E, Cignetti A, Aglietta M, Fagioli F. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. *J Clin Med.* 2021 Mar 11;10(6):1173. doi: 10.3390/jcm10061173. PMID: 33799685; PMCID: PMC7998305.

Palmerini E, Sanfilippo R, **Grignani G**, Buonadonna A, Romanini A, Badalamenti G, Ferraresi V, Vincenzi B, Comandone A, Pizzolorusso A, Brunello A, Gelsomino F, Pas T, Ibrahim T, Grosso F, Zanelli F, Pantaleo MA, Milesi L, Ciuffreda L, Ferrari V, Marchesi E, Quattrini I, Righi A, Setola E, Carretta E, Picci P, Ferrari S. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. *Cancers (Basel)*. 2021 Mar 2;13(5):1053. doi: 10.3390/cancers13051053. PMID: 33801399; PMCID: PMC7958606.

Tseng WW, Barretta F, Conti L, **Grignani G**, Tolomeo F, Albertsmeier M, Angele MK, Rutkowski P, Skoczylas J, De Paoli A, Navarria F, Raut CP, Fairweather M, Farma JM, Nessim C, Goel N, Grignol VP, Ford SJ, Cardona K, Subhawong T, Tattersall HL, Lee RM, Hu JS, von Mehren M, Sanfilippo R, Gronchi A. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Cancer*. 2021 Mar 1;127(5):729-738. doi: 10.1002/cncr.33323. Epub 2020 Nov 18. PMID: 33206381.

Tattersall HL, Hodson J, Cardona K, Lee RM, Nessim C, Gladdy R, Van Der Hage J, Schrage Y, Tseng WW, van Houdt W, Novak M, **Grignani G**, Tolomeo F, Goel N, Ryon E, Gyorki D, Bagaria SP, Gonzalez JA, Arnau ABM, Sayyed R, Tirota F, Evenden C, Desai A, Almond M, Glasbey J, Fiore M, Gronchi A, Ford SJ. Primary mesenteric sarcomas: Collaborative experience from the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *J Surg Oncol*. 2021 Mar;123(4):1057-1066. doi: 10.1002/jso.26353. Epub 2020 Dec 23. Erratum in: *J Surg Oncol*. 2021 Sep;124(3):457. PMID: 33368277.

Grignani G, Chiarion Sileni V, Pinto C, Depenni R, Fazio N, Galli L, Giuffrida D, Carnaghi C, Ciliberto D, Corsi DC, Queirolo P, Benincasa E, Venturini F, Fazzi G, Costa N, Ascierto PA. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. *J Transl Med*. 2021 Feb 15;19(1):70. doi: 10.1186/s12967-021-02730-8. PMID: 33588870; PMCID: PMC7885451.

Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Rutkowski P, Blay JY, Strauss D, Gonzalez R, Ahuja N, **Grignani G**, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Swallow CJ, Bagaria SP, Canter RJ, Mullen JT, Schrage Y, Pennacchioli E, van Houdt W, Cardona K, Fiore M, Gronchi A, Lahat G. Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). *Ann Surg Oncol*. 2021 May;28(5):2705-2714. doi: 10.1245/s10434-020-09445-y. Epub 2021 Jan 2. PMID: 33389288.

Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Blay JY, Strauss D, Rutkowski P, Ahuja N, Gonzalez R, **Grignani G**, Quagliuolo V, Stoeckle E, Lahat G, De Paoli A, Pillarisetty VG, Canter RJ, Mullen JT, Pennacchioli E, van Houdt W, Swallow CJ, Schrage Y, Cardona K, Fiore M, Gronchi A, Bagaria SP. Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Surg Oncol.* 2021;doi: 10.1245/s10434-021-10024-y.

D'Ambrosio L, Touati N, Blay JY, **Grignani G**, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer.* 2020;126(11):2637-2647. doi: 10.1002/cncr.32795.

Leuci V, Donini C, **Grignani G**, Rotolo R, Mesiano G, Fiorino E, Gammaitoni L, D'Ambrosio L, Merlini A, Landoni E, Medico E, Capellero S, Giraudo L, Cattaneo G, Iaia I, Pignochino Y, Basiricò M, Vigna E, Pisacane A, Fagioli F, Ferrone S, Aglietta M, Dotti G, Sangiolo D. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. *Clin Cancer Res.* 2020;26(23):6321-6334. doi: 10.1158/1078-0432.CCR-20-0357.

Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, Guercio M, Milano GM, Tamborini E, Busico A, Dagrada G, Garofalo C, Caruso C, Brunello A, Pignochino Y, Berrino E, **Grignani G**, Scotlandi K, Parra A, Hattinger CM, Ibrahim T, Mercatali L, De Vita A, Carriero MV, Pallocca M, Loria R, Covello R, Sbaraglia M, Dei Tos AP, Falcioni R, Maestro R. Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. *Front Oncol.* 2020;10:489. doi: 10.3389/fonc.2020.00489.

Grignani G, Merlini A, Sangiolo D, D'Ambrosio L, Pignochino Y. Delving into PARP inhibition from bench to bedside and back. *Pharmacol Ther.* 2020;206:107446. doi: 10.1016/j.pharmthera.2019.107446.

Chiabotto G, **Grignani G**, Todorovic M, Martin V, Centomo ML, Prola E, Giordano G, Merlini A, Miglio U, Berrino E, Napione L, Isella C, Capozzi F, Basiricò M, Marsero C, Gerardi I, Venesio T, Sangiolo D, Aglietta M, D'Ambrosio L, Pignochino Y. Pazopanib and Trametinib as a Synergistic

Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. *Cancers (Basel)*. 2020;12(6):1519. doi: 10.3390/cancers12061519.

Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, **Grignani G**, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. *J Clin Oncol*. 2020;38(19):2178-2186. doi: 10.1200/JCO.19.03289.

Trama A, Badalamenti G, Baldi GG, Brunello A, Caira M, Drove N, Marrari A, Palmerini E, Vincenzi B, Dei Tos AP, **Grignani G**. Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. *Cancer Epidemiol*. 2019;59:258-264. doi: 10.1016/j.canep.2019.02.012.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz- Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, **Grignani G**, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single- arm, phase 2 trial. *Lancet Oncol*. 2019;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4.

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. *Lancet Oncol*. 2018 (10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8.

Leuci V, Casucci GM, **Grignani G**, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. *Oncoimmunology*. 2018; 7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. PMID: 29721373; PMCID: PMC5927525.

Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, **Grignani G**, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P,

Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. *JAMA Oncol.* 2018;4(9):e180219. doi: 10.1001/jamaoncol.2018.0219.

Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, Gronchi A, Vincenzi B, **Grignani G**, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. *Mol Cancer Res.* 2017;15(5):553-562. doi: 10.1158/1541-7786.MCR-16-0376.

D'Ambrosio L, Palesandro E, Boccone P, Tolomeo F, Miano S, Galizia D, Manca A, Chiara G, Bertotto I, Russo F, Campanella D, Venesio T, Sangiolo D, Pignochino Y, Siatis D, De Simone M, Ferrero A, Pisacane A, Dei Tos AP, Aliberti S, Aglietta M, **Grignani G**. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. *Eur J Cancer.* 2017;78:122-132. doi: 10.1016/j.ejca.2017.03.025.

Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, **Grignani G**. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. *Mol Cancer.* 2017;16(1):86. doi: 10.1186/s12943-017-0652-5.

Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, **Grignani G**, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncol.* 2017;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0.

Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, **Grignani G**, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021):

an international, multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2017;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9.

Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, Aglietta M, **Grignani G**, Lampronti I, Fiorino E, Malavasi F, Sangiolo D, Gambari R, Ferrari D. Analytic and Dynamic Secretary Profile of Patient-Derived Cytokine-Induced Killer Cells. *Mol Med.* 2017;23:235-246. doi: 10.2119/molmed.2017.00084.

Demetri GD, Schöffski P, **Grignani G**, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. *J Clin Oncol.* 2017 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605.

Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. *Ann Oncol.* 2012;23(2):508-16. doi: 10.1093/annonc/mdr151.

Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. *Lancet Oncol.* 2015;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2.

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, **Grignani G**, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2016 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0.

Candiolo, 14/01/2022

Dr. Giovanni Grignani

